Fig. 4: Demonstration of the change in sBCMA level between sample collection 1 and 2 in paired patient samples, accounting for the variability in the time between sample collection.
From: Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients

The change in sBCMA is shown for patients with A MGUS who did not progress to MM (n = 49), B MGUS patients who did progress to MM (n = 42), and C SMM patients who progressed to MM (n = 29).